ArticleThe Kaohsiung journal of medical sciences2025
LINC01871 facilitates cervical cancer cell migration and immune escape by targeting miR-873-3p/MAP3K2 axis.
Article in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mitochondrial reprogramming in cervical cancer: crosstalk with tumor immunity, HPV oncogenic signaling, and therapeutic resistance.Frontiers in immunology · 2026Review
- lncRNA TMEM147-AS1 promotes acute myeloid leukemia development by regulating miR-873-3p/ZFX axis.Journal of molecular histology · 2025Article
- Bibliometric analysis of research on cervical cancer and miRNAs from 2010 to 2024: research trends, hotspots, and prospects.Discover oncology · 2025Article
- LINC01871 facilitates cervical cancer cell migration and immune escape by targeting miR-873-3p/MAP3K2 axis.The Kaohsiung journal of medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cervical cancer (CC) poses a significant threat to women's health and lives worldwide. Emerging evidence indicates that long noncoding RNA LINC01871 is closely associated with immune regulation in CC patients. However, its specific role and underlying mechanisms in CC remain poorly understood. In this study, we examined the expression levels and subcellular localization of LINC01871 in CC cell lines. Functional assays, including transwell migration and invasion assays as well as macrophage phagocytosis assays, were conducted to estimate CC cell invasiveness, migration, and immune response. Western blotting was performed to assess the protein expression of markers associated with epithelial-mesenchymal transition (EMT), immunity, and MAPK signaling. A luciferase reporter assay was used to confirm the interactions between LINC01871, miR-873-3p, and MAP3K2. Additionally, a xenograft mouse model was employed to investigate the in vivo effects of LINC01871 on CC progression. Our results revealed that LINC01871 is highly expressed and predominantly localized in the cytoplasm of CC cell lines. LINC01871 knockdown significantly suppressed CC cell invasion, migration, EMT, and immune escape in vitro and reduced tumor growth in vivo. Mechanistically, LINC01871 was found to interact with miR-873-3p, leading to the upregulation of MAP3K2 and subsequent activation of MAPK signaling. Furthermore, MAP3K2 overexpression rescued the inhibitory effects of LINC01871 silencing on the malignant behaviors of CC cells. In conclusion, LINC01871 facilitates CC metastasis by driving EMT and modulating the immune response via the miR-873-3p/MAP3K2/MAPK signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.